Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 4414

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 17

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Delivery
  • Disease
  • Hormones
  • Tobacco

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4414

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.

This modification of the royalties does not apply for the products Estradiol single gel, Testosterone single gel and the combination product Estradiol plus Testosteron” but only and exclusive for E2-NETA Combi Gel.

License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2: where estradiol is the sole active ingredient, and where the gel is applied to the skin Gel Testosterone: where testosterone is the sole active ingredient and where the gel is applied to the skin
Patch E2: where estradiol is the sole active ingredient and where the patch is applied to the skin
E2-**** Combi Gel: where estradiol and *********** are the two active ingredients and where the gel is applied to the skin
Option regarding E2-T Combi gel
E2-T Combi Gel: where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin

Products shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 27099

License Grant
The Swiss Company has granted Licensee an exclusive license, with the right to grant sublicenses for the licensing of E2/T Combi-Gel.E2/T Combi-Gel covers four hormone products for the treatment of hormone deficiencies in men and women.
License Property
Patents
5,891,462 – A Novel Composition for transdermal administration of an Estrogen, a Progestin or a mixture thereof (Combi Gel)
08/058,517 – Administration System for Estradiol (Estradiol Patch)

Products
Gel E2 (where Estradiol is the sole active ingredient, and where the gel is applied to the skin) Gel Testosterone (where testosterone is the sole active ingredient and where the gel is applied to the skin)
Patch E2 (where Estradiol is the sole active ingredient and where the patch is applied to the skin)
E2-**** Combi Gel (where Estradiol and *********** are the two active ingredients and where the gel is applied to the skin)
Option regarding E2-T Combi gel
E2-T Combi Gel (where Estradiol and Testosterone are the two active ingredients and where the gel is applied to the skin)

Field of Use
The rights granted apply to the Products which shall mean the four pharmaceutical products either dermal gel or patch, for application on the skin, intended for pharmaceutical use with humans for any indication now known or known in the future, and with defined active compounds.

IPSCIO Record ID: 6946

License Grant
The Swiss Licensor has granted the Licensee the licensing of XXXX Combi-Gel  with the right to sublicense products.

The Licensor and the Licensee have entered into that certain License and Supply Agreement dated of June 13, 2000, regarding the grant of a License with the right to subLicense products.  This amendment is effective  as defined in the Agreement

License Property
This modification of the royalties only applies and is exclusive for E2-NETA Combi Gel.

IPSCIO Record ID: 28841

License Grant
Swiss Licensor hereby grants to the Dutch Licensee the exclusive, sub-licensable right and License to pursue the development in accordance with the Development Plan as required in order to apply for Registration(s) for the Combi-Gel NETA, and upon receipt of such Registration, to manufacture, market, distribute and sell the Product, in the Territory, and to use the Patents and Know-How exclusively for that purpose, all in accordance with the provisions contained in this Agreement and subject to the payment of the Milestone Payments and the Royalty.
License Property
'Combi-Gel NETA' shall mean the Combi-Gel containing Estradiol and Norethindrone acetate in all concentrations as the sole active ingredients for pharmaceutical use with humans developed by Licensor prior to the effective date of this Agreement.

Combi Gel NETA is a transparent, non-staining gel to be applied once-a-day in postmenopausal women.   Based on Licensor's Combi Gel Technology, it delivers transdermal levels of two hormones: 17-beta Estradiol and Norethindrone Acetate.  This technology will be used for the development of a hormone replacement therapy gel.

Patent Application Number: 08/869,982
Date of Application: 05/06/97

IPSCIO Record ID: 203450

License Grant
Licensor grants an exclusive license in the Territory, and, the right to grant sub licenses, to rights under:
(a) the Licensor Patents and Technology; and
(b) Licensors rights in any Joint Developments in the Field;
in each case to develop, use, make, have made, sell or otherwise dispose of the Products in the Field; provided, however, that notwithstanding the foregoing, Licensee shall not have the right to make or have made the Products other than as expressly contemplated by or provided in the Manufacturing and Supply Agreement, or to modify in any way the structure or composition of the Products, without the prior written consent of Licensor.
License Property
The patents cover the T-Patch and/or the TE Patch.

Products means the TE Patch and the T-Patch. For the avoidance of doubt, Products does not include Intrinsa.

The Once A Week T Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain testosterone as the single active ingredient at a dosage in vitro of testosterone to be determined, that is intended to be worn for seven consecutive days, which shall be evidenced by either an NDA or a supplement to the NDA for the T Patch or lntrinsa.

The T-Patch means the transdermal patch drug delivery system developed by Licensor that contains testosterone as the single active ingredient at an in vivo dosage bio-equivalent to Intrinsa which is worn for three to four consecutive days, which shall be evidenced by either an NDA, a supplement thereto, or a supplement to the NDA, for Intrinsa, and shall include any minor improvements or modifications to such product that do not require additional development work.

The TE Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain as the active ingredients a combination of testosterone and estrogen at a single dosage in vivo of testosterone to be determined, which dosage shall be in the range of about 50 to about 600 meg/day and which shall he evidenced by an NDA or a supplement thereto.

Field of Use
The Field means transdermal patches that contain testosterone ( or androgen derivatives of testosterone or androgens that convert to testosterone in the body) as the single active ingredient, and transdermal patches that contain the combination of testosterone (or androgen derivatives of testosterone or androgens that convert to testosterone in the body) plus estrogen or other related hormones (e.g. progestin), in each case at dosages of testosterone, androgen derivatives of testosterone or androgens that convert to testosterone in the body (in vivo) in the range of about 50 to about 600 meg/day, for use by women for any indication.

IPSCIO Record ID: 30630

License Grant
The company signed a non-exclusive license agreement  for the 7-day Estradiol patch.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 30091

License Grant
The company entered into a non-exclusive license agreement for the 7-day Estradiol patch for Chile, and an exclusive license for the Estradiol patch for Bolivia and Ecuador.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 6955

License Grant
The Licensor granted the Licensee an exclusive license to certain patents and patent applications covering certain gel products, including rights to sublicense, in order to develop and market the products in certain territories, including the U.S., Canada, New Zealand, South Africa, Israel, Mexico, China (including Hong Kong) and Indonesia.
License Property
Our products for female sexual health, menopause, contraception and male hypogonadism include our gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen: LibiGel, Elestrin, Bio-T-Gel and Pill-Plus, our triple component contraceptive that uses various combinations of estrogens, progestogens and androgens in development for the treatment of FSD in women using oral or transdermal contraceptives.
Field of Use
The rights granted apply to the healthcare for women.

The Licensee is the exclusive licensee in certain territories for issued U.S. patents for these products and additional patent applications have been filed for this licensed technology in the U.S. and several foreign jurisdictions.

IPSCIO Record ID: 145984

License Grant
The Italian Licensee entered into an exclusive license agreement for the Licensors 7-day Estradiol patch for Italy, the Vatican and San Marino (the Territories).
License Property
The 7-day Estradiol patch is a product for the delivery of drug compounds through skin and mucosa.  Estradiol transdermal skin patches are used to treat certain symptoms of menopause.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 30085

License Grant
The company entered into a non-exclusive license agreement for the 7-day Estradiol patch for Chile.
License Property
Estradiol is a hormone replacement therapy for menopausal women.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 28250

License Grant
In May 2015, the Licensee acquired from the Licensor the approved new drug application for the previously-Licensed testerone gel product. Pursuant to the terms of the purchase Agreement, upon commercialization, the Licensee will pay a royalty as a result of commercial sale of the product.
License Property
The Licensor's Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism.
Field of Use
The Licensee acquired a testosterone gel product for commercialization.

IPSCIO Record ID: 6580

License Grant
The Licensor and Licensee have a license agreement for the Licensor's CPE-215 with Testosterone formulation – Testim.  Testim was was launched in the U.S. in early 2003. The Licensor recently obtained patents that cover the application of testosterone with CPE-215 in the U.S. and in foreign countries that continue through 2023.
License Property
The Licensor's platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through development of proprietary formulations with molecules such as CPE-215.

Testim® is a gel for testosterone replacement therapy, which is a formulation of our technology with testosterone.

IPSCIO Record ID: 230786

License Grant
Licensor grants to Licensee of the Netherlands and Licensees Affiliates an exclusive, even as to Licensor, license right, with the right to grant sublicenses, to use and exploit Licensor IP Rights to import, market, sell and distribute the Product, in the Territory, in the Field.

Licensor also grants to Licensee the right to file Marketing Authorization Applications outside EU countries and to seek pricing and reimbursement approvals where required.

Licensor also grants to Licensee an exclusive, license right, with the right to grant sublicenses, to use the Trademark on and solely in connection with the commercialization of the Product throughout the Territory, in the Field.

License Property
Product means a pharmaceutical composition containing testosterone as the single active drug ingredient and CPE 215 which fall within the scope of any composition, method or claim of Licensor IP Rights and which is intended to be applied topically, including TESTIM 1% testosterone gel.

Trademark means TESTIM.

Field of Use
Field means the use of Product for testosterone replacement therapy to restore serum testosterone in adult males with primary and secondary hypogonadism or such equivalent or similar indication as authorized on a country-by-country basis, and any additional indications based on the existing dossier which do not require extra development work (to the exclusion of regulatory work); such additional indications, if initiated by Licensee, are subject to approval by Licensor.

Competing Product means all transdermal products containing testosterone as an active ingredient used for testosterone replacement therapy to restore serum testosterone in adult males with primary and secondary hypogonadism or such equivalent or similar indication.

IPSCIO Record ID: 570

License Grant
The Company shall sell, assign, transfer, convey and deliver to Purchaser, and Purchaser shall purchase, acquire and accept from the Company, all of the Company's right, title and interest in and to those certain assets  (the 'Intellectual Property').
License Property
The Company has developed and owns the certain Intellectual Property which it refers to as the 'U-Strip' Technology.

The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.

Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.

IPSCIO Record ID: 27699

License Grant
Licensor, for itself and its Affiliates, grants to Licensee and its Affiliates in accordance with the terms and conditions of this Agreement, the exclusive right (even as to Licensor and its Affiliates), under all of the existing or future Product Know-How owned or controlled by Licensor or its Affiliates, to register, make or have made, develop, import/export or have imported/exported, use or have used, Market, offer for sale or have sold, and otherwise exploit the Product on a sole and exclusive basis (even as to Licensor and its Affiliates) in or for the Territory.
License Property
The Product: 1% testosterone gel AB-rated to AndroGel®; male testosterone gel as an AB-rated equivalent to AndroGel.

AB-rated drugs are drugs that meet the necessary bio-equivalence standards established by the Food and Drug Administration (FDA).

The Licensee will make certain upfront and milestone payments to the company.

The stated royalty rate will increase during the period of time if the Licensee markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel® in the United States.

The Licensee is a generic drug manufacturer.

Field of Use
AndroGel® (testosterone gel) 1% and 1.62% are controlled substances, available by prescription, used to treat adult males who have low or no testosterone.

IPSCIO Record ID: 3997

License Grant
The Licensor granted us an exclusive License to certain products, including rights to subLicense the products, in order to develop and market the products in certain territories. The Licensee is the exclusive Licensee in certain territories for a Licensor issued patent for these products in the United States and has filed additional patent applications (several that include Licensee personnel as inventors) for this Licensed technology in the U.S. and several foreign jurisdictions.
License Property
We License the technology underlying certain of our products from the Licensor.
Field of Use
The Licensee is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. Our primary products are gel formulations of testosterone and estradiol.  We also are engaged in the development of our proprietary calcium phosphate nanotechnology, or CaP, primarily for aesthetic medicine, novel vaccines and drug delivery.

IPSCIO Record ID: 7311

License Grant
Licensor, for itself and its Affiliates, grants to Licensee and its Affiliates in accordance with the terms and conditions of this Agreement, the exclusive right (even as to Licensor and its Affiliates), under all of the existing or future Product Know-How owned or controlled by Licensor or its Affiliates, to register, make or have made, develop, import/export or have imported/exported, use or have used, Market, offer for sale or have sold, and otherwise exploit the Product on a sole and exclusive basis (even as to Licensor and its Affiliates) in or for the Territory.
License Property
The Product: 1% testosterone gel AB-rated to AndroGel®; male testosterone gel as an AB-rated equivalent to AndroGel.

AB-rated drugs are drugs that meet the necessary bio-equivalence standards established by the Food and Drug Administration (FDA).

The Licensee will make certain upfront and milestone payments to the company.

The stated royalty rate will increase during the period of time if the Licensee markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel® in the United States.

The Licensee is a generic drug manufacturer.

Field of Use
AndroGel® (testosterone gel) 1% and 1.62% are controlled substances, available by prescription, used to treat adult males who have low or no testosterone.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.